York / MSAC / PHARMAC / Secretariat / INAHTA / Countries / Kaiser Permanente / CADTH / PBAC / Woden / London / /
Company
Novartis / Cambridge University Press / GlaxoSmithKline / Merck / Western European / Agency for Healthcare Research / CIRIT / Banta / Cargill / Johnson and Johnson / Health Technology Assessment International / Medtronic / Pfizer / Canadian Agency for Drugs / AstraZeneca / /
Continent
Europe / /
Country
Switzerland / Netherlands / Norway / Japan / Canada / Australia / United Kingdom / India / Germany / Italy / New Zealand / United States / Spain / Belgium / / /
Facility
University of York / Market Square / Paul Trueman University of York Karen Facey HTAi Policy Forum As / National Institute / Managed Care Pharmacy / Woodlands Lodge / /
IndustryTerm
public healthcare purchasing organizations / technology assessment reports / pharmaceutical industry / health technologies / technology assessment / pharmaceuticals / individual technologies / prevention of heart disease / health products / healthcare resource use / local healthcare system / health systems / technology reimbursement/coverage decisions / technologies / medical technologies / healthcare organization / healthcare resource unit costs / inclusive networks / healthcare / local healthcare systems / hurdle systems / technology decisions / individual technology level / umbrella pharmaceutical industry association / particular technology / healthcare technology manufacturers / to all technologies / healthcare interventions / decision-making systems / technology manufacturers / pharmaceutical products / decision-making processes / /
MedicalCondition
diabetes / each particular disease / common disease / heart disease / disease / lar disease / cardiovascular disease / /
Organization
Cambridge University / Pharmaceutical Benefits Advisory Committee / EUnetHTA / Global Harmonisation Task Force / Government of Catalonia / National Institute for Health and Clinical Excellence / European Commission / Scientific Advisory Board of CIRIT / European Union / Harvard Medical School / Canadian Agency for Drugs and Technologies / University of York / Australia New Zealand Therapeutic Products Authority / Canadian Coordinating Office for Health Technology Assessment / Academy of Managed Care Pharmacy / Agency for Healthcare Research and Quality / /
Person
Franz Waibel / Andrea Rappagliosi / Lloyd Sansom / Jean Francois Baladi / Hilda Bastian / Jean Slutsky / Clare McGrath / Neil Johnson / Sandy Pagotto / Frances Charlesworth / John Arne Røttingen / Bert Boer / Kathy Cargill / Carole Longson / Nick Bruce / Stephen Dellar / Dave Ames / John Sproule / Andrew Mitchell / Alicia Granados / Guy Maddern / Steve Pearson / Americo Cicchetti / Brendon Kearney / Ken Stein / Caroline Lowe / Mitchell Sugarman / Michael Rawlins / Matthew Brougham / John Hutton / Chris Henshall / Laura SampietroColom / Jens Grueger / Jeff Kirsch / Milena Richter / Marguerite Koster / Catherine Farrell / Karen Facey / Paul Trueman / Peter de Jong / /
Position
Board Director / USA / general data standards / Director / York Health Economics Consortium / Board Director / Italy; / Professor / Executive / Board Director / Australia; Berit Morland / forward / Board Director / Norway; Wija Oortwijn / Board Director / Board President / Chair / /
ProvinceOrState
Ontario / /
Technology
health technologies / particular technology / http / drug development / /
International Journal of Technology Assessment in Health Care, 24:[removed]), 511–517. c 2008 Cambridge University Press. Printed in the U.S.A. Copyright doi:[removed]S0266462308080677 COMMENTARIES, VIEWS, AND